Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Listen to this summary
This study investigates how the combination of genetic risk factors and measurable residual disease (MRD) can inform therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The authors aim to determine the efficacy of using centrally assessed MRD and genetic profiles to identify patients suitable for allogeneic hematopoietic stem cell transplant (alloHSCT) versus those who can be treated with chemotherapy. Results indicate that this combined approach enhances the precision of treatment decisions and improves overall survival outcomes for patients.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Blood
View all →May 8, 2026 · Blood
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies
May 8, 2026 · Blood
Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals
May 7, 2026 · Blood
JMJD1C-mediated epigenetic control of autoimmunity and HIT antibody production
May 7, 2026 · Blood
How I utilize somatic alterations in the diagnosis, risk stratification, and therapy of hypocellular bone marrow failure
May 7, 2026 · Blood
Bone Marrow Stem Cell Connexins: Misconceptions and New Insights
May 7, 2026 · Blood
Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia
More in Internal Medicine
View all →May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026 · European heart journal
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · European heart journal
Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial
May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
